


Aizenberg, A. (2000), ‘Teva CEO: in 1999 we have established our position as the world’s leading generic company (Hebrew Translation)’, Maariv, Tel-Aviv, 15 February.


Association of the British Pharmaceutical Industry (ABPI) (2000a), 


References


Boyle, J. (2001), ‘Whigs and hackers in Cyberspace – copyrights regulations before the European Parliament should be treated as sceptically as they were by the Victorians’, *Financial Times*, 12 February.


The international political economy of intellectual property rights


Commission of the European Communities (1988), Green Paper on Copyright and the Challenge of Technology: Copyright Issues Requiring Immediate Attention, Brussels.
Commission of the European Communities (1992), *Impediments to Parallel Trade in Pharmaceuticals Within the European Community*, Brussels.


Commission of the European Communities (2001b), *Questions on TRIPs and Data Exclusivity – An EU Contribution*, Brussels.

Commission of the European Communities (2001c), *Review of the Provisions of Article 27.3(b) of the TRIPS Agreement – Draft Communication by the European Communities and Their Member States on the Relationship Between the Convention on Biodiversity and the TRIPS Agreement – Submitted by the Commission to the Article 133 Committee*, Brussels: 23 February.


*The Economist* (1851), 26 July, p. 812.
The Economist (1999b), Balms for the Poor, 14–20 August, pp. 63–5.


European Chemical Industry Council (2000a), Annual Report 1999, Brussels: CEFIC.
European Chemical Industry Council (2000b), ‘Focus on CEFIC – Statutory Bodies’, Brussels: CEFIC.


European Court of Justice (1994), ‘Opinion 1/94 of the Court of Justice: Competence of the Community to conclude international agreements concerning services and the protection of intellectual property – Article 228(6) of the EC Treaty’, Luxembourg: 15 November.


European Federation of Pharmaceutical Industries and Associations (EFPIA) (1998b), The Pharmaceutical Industry in Figures, Brussels: EFPIA.

European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999a), The Pharmaceutical Industry in Figures – Key Data 1999 Update, Brussels: EFPIA.


European Federation of Pharmaceutical Industries and Associations (EFPIA) (1999j), Press release, ‘The pharmaceutical industry is contributing to improve
healthcare in developing countries and participates in global actions that pave the way for better global public health’, Brussels: 23 November.


European Federation of Pharmaceutical Industries and Associations (EFPIA) (2000d), ‘It is vital that the European commission moves further along the market liberalisation route of the pharmaceutical sector’, says Jorge Gallardo, EFPIA President to Romano Prodi’, Brussels: EFPIA: 22 June.


Financial Times Survey (2000), FT 500, 4 May.


Chairman, Trade Policy Staff Committee, Office of the United States Trade Representative, Washington DC: IPC, 19 October.


Inside US Trade (2001), EU Withdraws TRIPs Compromise Proposal Opposed by Member States, 26 October.


International Federation of Pharmaceutical Manufacturers Associations (IFPMA) (2001b), Press release ‘The research-based pharmaceutical industry agrees with the Doha WTO Ministers that intellectual property protection is vital to trade, access and innovation’, Geneva: IFPMA, 14 November.


INTERPAT (1998a), ‘INTERPAT Statutes, as accepted by the General Assembly’, 23 March.


Kinnock, G., Member of the European Parliament (2001), ‘Drug companies should drop their case and save face’, Financial Times, letters to the Editor, 9 March.


Lamy, P., European Commissioner for Trade (2001), ‘Europe has listened, Europe has moved, and Europe is willing to go the extra mile’, statement by Pascal Lamy at opening press conference, WTO Ministerial Meeting, Doha, 9 November 2001.


Miller, C., Director of Programmes, Save the Children (2001), ‘Pharmaceutical companies attack the world poorest’, Financial Times, Letters to the Editor, 14 February.


Office of the Prime Minister, United Kingdom (2000), *Joint Statement by the Prime Minister Tony Blair and President Clinton on Human Genetic Research*, 14 March.


Pharmaceutical Researchers and Manufacturers Association of America (PhRMA) (1999), Industry Profile 1999, Washington DC: PhRMA.

Pharmaceutical Researchers and Manufacturers Association of America (PhRMA) (2003), Industry Profile 2003, Washington DC: PhRMA.


Pilling D. (2001c), ‘Third world and drugs groups remain wary of each other’, Financial Times, 10 July.


Republic of South Africa (1997), Medicines and Related Substances Control Amendment Act No. 90, 23 November.


The international political economy of intellectual property rights


References

Scrip (1997), EFPIA To Allow Company Membership, No. 2216, 21 March.
Scrip Magazine (1993), Teva – a Small Company with Big Ideas, April, pp. 40–41.


UNAIDS (2000a), South Africa – Epidemiological Fact Sheet on HIV/AIDS and Sexually Transmitted Infections, Geneva: UNAIDS.


United Industrial and Employers Confederation of Europe (UNICE) (1990), ‘UNICE initial comments on the draft final Act of the Uruguay Round’, Brussels: 10 January.


United Nations Conference on Trade and Development (UNCTAD) (1979), *The Role of Trade Marks in Developing Countries*, New York: UNCTAD.


United States Information Agency (1999), ‘Recommendation for evaluation of implementation pursuant to Paragraph 8 of the Geneva ministerial declaration – Communication from the United States’, USIA.


United States Trade Representative (USTR) (1998a), Reports Issued by the Office of the United States Trade Representative and Related Entities – Section 301 Table of Cases – Korea Intellectual Property Rights (301–52), Washington DC: USTR 4 June.

United States Trade Representative (USTR) (1998b), Reports Issued by the Office of the United States Trade Representative and Related Entities –
Section 301 Table of Cases – Korea Intellectual Property Rights – Brazil Pharmaceuticals (301–61), Washington DC: USTR, 4 June.


Vaitsos, C.V. (1971), Transferencia de recursos y preservación de rentals monopolísticos, Revisita de Planeation Desarrollo, Bogota, Colombia: July, pp. 56–7.


WTO – Council for TRIPs (2001a), Ministerial Declaration on the TRIPs Agreement and Public Health – Proposal by the African Group, Bangladesh, Barbados, Bolivia, Brazil, Cuba, Dominican Republic, Ecuador, Haiti, Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, Philippines, Peru, Sri Lanka, Thailand and Venezuela, Geneva: 4 October, document number: IP/C/W/312.


WTO – Ministerial Conference (1996a), *Statement by H.E. Felipe Jaramillo, Vice Minister of Foreign Trade, Colombia*, 9 December, document number: WT/MIN(96)/ST/23.


WTO – Ministerial Conference, Third Session (1999a), Statement by H.E. Mr Murasoli Maran, Minister of Commerce and Industry, India, 30 November, document number: WT/MIN(99)/ST/16.


WTO – Ministerial Conference, Third Session (1999e), Statement by H.E. Mr Khalifa Ababacar Sall, Minister of Commerce and Handicrafts, Senegal, 1 December, document number: WT/MIN(99)/ST/61.

WTO – Ministerial Conference, Third Session (1999f), Statement by Dr Reginaldo Panting P., Secretary of State for Industry and Trade, Honduras, 1 December, document number: WT/MIN(99)/ST/40.


